TY - JOUR T1 - Reaching collective immunity for COVID-19: an estimate with a heterogeneous model based on the data for Italy JF - medRxiv DO - 10.1101/2020.05.24.20112045 SP - 2020.05.24.20112045 AU - Andrey Gerasimov AU - Georgy Lebedev AU - Mikhail Lebedev AU - Irina Semenycheva Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/25/2020.05.24.20112045.abstract N2 - Background At the current stage of COVID-19 pandemic, forecasts become particularly important regarding the possibility that the total incidence could reach the level where the disease stops spreading because a considerable portion of the population has become immune and collective immunity could be reached. Such forecasts are valuable because the currently undertaken restrictive measures prevent mass morbidity but do not result in the development of a robust collective immunity. Thus, in the absence of efficient vaccines and medical treatments, lifting restrictive measures carries the risk that a second wave of the epidemic could occur.Methods We developed a heterogeneous model of COVID-19 dynamics. The model accounted for the differences in the infection risk across subpopulations, particularly the age-depended susceptibility to the disease. Based on this model, an equation for the minimal number of infections was calculated as a condition for the epidemic to start declining. The basic reproductive number of 2.5 was used for the disease spread without restrictions. The model was applied to COVID-19 data from Italy.Findings We found that the heterogeneous model of epidemic dynamics yielded a lower proportion, compared to a homogeneous model, for the minimal incidence needed for the epidemic to stop. When applied to the data for Italy, the model yielded a more optimistic assessment of the minimum total incidence needed to reach collective immunity: 43% versus 60% estimated with a homogeneous model.Interpretation Because of the high heterogeneity of COVID-19 infection risk across the different age groups, with a higher susceptibility for the elderly, homogeneous models overestimate the level of collective immunity needed for the disease to stop spreading. This inaccuracy can be corrected by the homogeneous model introduced here. To improve the estimate even further additional factors should be considered that contribute to heterogeneity, including social and professional activity, gender and individual resistance to the pathogen.Funding This work was supported by a grant from the Ministry of Education and Science of the Russian Federation, a unique project identifier RFMEFI60819X0278.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from the Ministry of Education and Science of the Russian Federation, a unique project identifier RFMEFI60819X0278.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a modeling study that did not require any clinical protocol to be approved.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a modeling epidemiological study that uses online data repository. https://www.europeandataportal.eu/en/highlights/covid-19 ER -